[Eradication therapy and processes of proliferation and apoptosis in the stomach of patients with duodenal ulcer].
A total of 172 subjects were enrolled in the study including 100 with duodenal ulcer (DU), 30 with chronic non-atrophic gastritis (CNG), 30 with chronic atrophic gastritis (CAG), and 12 practically healthy controls. All DU, CNG, and CAG patients had Helicobacter pylori (Hp) infection confirmed by morphological study of gastric mucosa. Patients with DU were divided into 2 groups matched for age, endoscopic, morphological, and immunohistochemical characteristics. In group 1, Hp was eradicated by traditional therapy with omeprazole (20 mg), clarithromycin (500 mg), and amoxicillin (1000 mg) twice daily for 7days. This treatment in group 2 was supplemented by dibicor (500 mg twice daily). Thereafter, patients of group 1 continued to receive omeprazole for 6 weeks followed by maintenance therapy; those of group 2 received omeprazole plus dibicor for 6 weeks and maintenance therapy. CNG and CAG patients and healthy subjects served as controls. Fibrogastroduodenoscopy was performed after 2 and 4 weeks. CNG and CAG patients were examined for the presence of KI-67, BCL-2 regulators and apoptotic activity of epitheliocytes from antral mucosa before and 6 weeks after eradication therapy. It is concluded that its combination with dibicor significantly contributes to Hp elimination, shortens duodenal scarring time, improves KI-67, BCL-2 expression, and stimulates apoptotic activity of epitheliocytes compared with traditional omeprazole treatment.
Osadchuk
A M
AM
Milova-Filippova
L A
LA
Kvetnoĭ
I M
IM
D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects*; D049109:Cell Proliferation / Q000187:drug effects*; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000473:pathology; D016099:Endoscopy, Gastrointestinal; D005260:Female; D005500:Follow-Up Studies; D005753:Gastric Mucosa / Q000187:drug effects / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use*; D013654:Taurine / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
D000897:Anti-Ulcer Agents; D013654:Taurine; D009853:Omeprazole